You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

231 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
Jun 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Feb 2024
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Adjuvant
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Apr 2023
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Apr 2016
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Jun 2019
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
Jun 2019

Pages